Quick Answer
SAB Biotherapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $10.50 million for the year ending 2025.
- SAB Biotherapeutics, Inc. showed an increase of +18.0% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from SAB Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2020 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $20.13 million | Q2 2021: $10.23 million | Q3 2021: $10.75 million | Q3 2022: $8.33 million | Q1 2023: $13.06 million | Q2 2023: $7.77 million | Q3 2023: $2.43 million | Q1 2024: $14.03 million | Q2 2024: $17.24 million | Q3 2024: $9.17 million | Q1 2025: $5.64 million | Q2 2025: $3.69 million | Q3 2025: $29.42 million.
- Over the full 8 years of available data (2020 to 2025), SAB Biotherapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 16.7%.
- Historical annual values: Fiscal year 2025: $10.50 million | Fiscal year 2024: $8.90 million | Fiscal year 2023: $56.57 million | Fiscal year 2022: $15.05 million | Fiscal year 2022: $16.62 million | Fiscal year 2022: $22.41 million | Fiscal year 2021: $33.21 million | Fiscal year 2020: $12.61 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: